SCR 68 is a nonstatutory concurrent resolution that designates the week of May 5, 2025, as Tardive Dyskinesia Awareness Week in California. The resolution explains that tardive dyskinesia (TD) is a movement disorder associated with prolonged use of antipsychotic medications, which are often prescribed to treat serious mental illnesses such as bipolar disorder, major depressive disorder, and schizophrenia. It highlights that TD can cause uncontrollable, repetitive movements and that many people living with the condition remain undiagnosed.
The resolution emphasizes the importance of early screening, detection, and intervention, citing clinical guidance from the American Psychiatric Association and noting that FDA-approved treatments are available to help manage symptoms. It also encourages education and awareness among health care providers, patients, and care partners so that people prescribed antipsychotics receive routine TD screenings and appropriate follow-up care.
Impact
SCR 68 does not amend the California Codes or create a regulatory mandate; instead, it is an official legislative recognition and awareness resolution. Its practical effect is to promote public and professional awareness of tardive dyskinesia, encourage routine screening for patients taking antipsychotic medications, and support early intervention and treatment. The measure primarily affects health care providers, patients with serious mental illness, care partners, and advocacy/public health efforts rather than changing enforceable state law.
Sentiment
The bill appears to have been received very positively and without opposition. It passed the Senate 36-0, was adopted to the consent calendar 10-0, and later passed the Assembly consent calendar 75-0, indicating broad bipartisan support and little controversy. The resolution’s public health and awareness focus likely contributed to its unanimous votes.
Contention
There is little evidence of substantive contention in the available record, and no committee transcript concerns are provided. The only potential policy sensitivity is the resolution’s emphasis on antipsychotic prescribing and the risks associated with those medications, which could raise concerns about balancing awareness of side effects with the need for effective treatment of serious mental illness. However, the bill itself frames this as a screening and education issue, and the unanimous votes suggest no significant disagreement among legislators.